)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
L&C BIO
L&C BIO (290650) investor relations material
L&C BIO Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary14 Aug, 2026
Executive summary
The company specializes in human tissue grafts, tissue-based medical devices, cosmeceuticals, and related CRO services, with a strong focus on R&D and global expansion.
Major revenue drivers are human tissue grafts and medical devices, with expanding indications and international certifications.
The company completed full acquisition of its Chinese subsidiary and continues to invest in R&D and production capacity.
Financial highlights
Consolidated revenue for H1 2026 was KRW 69.1 billion, down from KRW 85.5 billion in FY2025.
Operating income for H1 2026 was KRW 14.6 billion, compared to a loss of KRW 25.4 billion in FY2025.
Net loss attributable to owners for H1 2026 was KRW -25.4 billion, improved from KRW -138.2 billion in FY2025.
Basic EPS for H1 2026 was KRW -990, compared to KRW -5,810 in FY2025.
Total assets at June 30, 2026: KRW 477.4 billion; equity: KRW 335.2 billion.
Outlook and guidance
The company plans a rights offering and public share issue of 3.7 million shares to raise capital for operations, facilities, and debt repayment, with payment due October 22, 2026.
Focus remains on expanding global market share, launching new products, and strengthening R&D pipeline.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from L&C BIO
- Strong revenue and margin growth offset by large non-cash losses from derivatives and impairment.290650
Q4 2025 - H1 2024 saw lower sales and profit, but strategic investments and R&D support future growth.290650Q2 2024
- Q1 2026 revenue and profit surged, supported by core tissue grafts and China expansion.290650Q1 2026
- H1 2025 saw a net loss amid lower sales, but strategic acquisitions and R&D investment continue.290650Q2 2025
- Revenue fell and net loss widened, but global expansion and R&D investment continued.290650Q3 2025
- Net income soared to KRW 141.0 billion on 9.4% revenue growth, driven by a major one-off gain.290650Q4 2024
- Q1 2025 posted a net loss amid robust R&D, global expansion, and new capital initiatives.290650Q1 2025
- Q3 2024 revenue and profit fell sharply year-over-year, but R&D and global expansion continue.290650Q3 2024
Next L&C BIO earnings date
Q3 202613 Nov, 2026
L&C BIO
Next L&C BIO earnings date
Q3 202613 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage